文献速递甲状腺疾病

大型甲状腺细针穿刺队列长期人群随访研究

A Large Thyroid Fine Needle Aspiration Biopsy Cohort with Long-Term Population-Based Follow-Up.
PubMed 文献 · Thyroid · 2021-01-29

该研究回顾性分析1997至2004年UCSF的2207例甲状腺细针穿刺(FNAB),按2017 Bethesda系统(TBSRTC)分类并链接癌症登记,中位随访13.9年。Kaplan-Meier分析显示非诊断性和良性类别恶性风险低,AUS/FLUS和滤泡性肿瘤中等,可疑和恶性类别高;假阴性率3.2%(排除微小乳头状癌后1.5%),无假阴性患者死于甲状腺癌。结论认为FNAB检测恶性高度准确,低风险且初始良性或不满意活检的无症状患者 unlikely 发生或死于甲状腺癌。

要点

  • FNAB对甲状腺恶性检测高度准确,假阴性率低。
  • 初始良性或不满意活检且低风险患者预后良好。
  • TBSRTC分类与长期恶性风险分层一致。

核心结论

  • FNAB检测甲状腺恶性高度准确,低风险初始良性或不满意活检患者极少发生或死于甲状腺癌。

研究设计与样本

  • 回顾性队列研究,纳入UCSF 1997-2004年2207例初始甲状腺FNAB,按2017 TBSRTC分类并链接癌症登记,中位随访13.9年。

主要发现

  • 随访期间确认279例甲状腺恶性。
  • Kaplan-Meier显示非诊断性和良性类别恶性风险低,AUS、FLUS、AUS/FLUS组合和滤泡性肿瘤中等,可疑和恶性类别高。
  • 假阴性52/1575例(3.2%),排除微小乳头状癌后为1.5%(23/1575)。
  • 假阴性诊断患者随访期间无死于甲状腺癌。

临床怎么用

  • 对无症状、临床和影像学低风险且初始良性或不满意活检患者,可考虑保守随访。
  • FNAB结果可结合TBSRTC分类用于恶性风险评估。

局限性

  • 研究为回顾性设计,需在采用TBSRTC和整合分子检测后进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Prior studies evaluating thyroid fine needle aspiration biopsies (FNABs) have limited the calculation of risk of malignancy (ROM) to cytologic specimens with corresponding histologic specimens, and clinical follow-up for those patients who do not undergo immediate surgery has been largely disregarded. Moreover, there is marked variability in how researchers have approached thyroid FNAB statistical analyses. This study addresses the urgent need for information from a large cohort of patients with long-term clinical follow-up to more accurately determine the performance of thyroid FNAB and ROM for each diagnostic category. Methods: A retrospective review of the University of California, San Francisco (UCSF), pathology database for thyroid FNABs from January 1, 1997, to December 31, 2004, was performed. Diagnoses were coded using the 2017 The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), and patients were matched to both the UCSF cancer registry and California Cancer Registry. Data were analyzed using the Kaplan-Meier method, and stratified by TBSRTC diagnostic category. Kaplan-Meier curves were used to estimate incidence rates of malignancy, stratified by FNAB category. Cox proportional hazards models were used to determine the instantaneous ROM. Results: Initial FNABs from 2207 patients were included. Median follow-up period after the first thyroid FNAB was 13.9 years (range: 10.5-18.4 years). During follow-up, there were 279 confirmed diagnoses of thyroid malignancy. Estimates derived from Kaplan-Meier curves demonstrated that the risk of having a thyroid malignancy was low for nondiagnostic and benign categories, intermediate for atypia of undetermined significance (AUS), follicular lesion of undetermined significance (FLUS), AUS/FLUS combined, and follicular neoplasm, and high for suspicious and malignant categories. A total of 52/1575 false-negative cases (3.2%) were identified. Excluding papillary microcarcinomas, the false-negative rate was 1.5% (23/1575). No patients with a false-negative diagnosis died of thyroid cancer during the follow-up period. Conclusions: Asymptomatic patients with low-risk clinical and radiologic features and initially benign or unsatisfactory biopsy are unlikely to develop thyroid malignancy and highly unlikely to die of thyroid cancer. FNAB is highly accurate in detecting malignancy. Additional studies evaluating similar large data sets after the adoption of TBSRTC and the integration of molecular testing are needed.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Ng DL, van Zante A, Griffin A, et al. A Large Thyroid Fine Needle Aspiration Biopsy Cohort with Long-Term Population-Based Follow-Up. Thyroid. 2021. PMID: 33371796. doi:10.1089/thy.2020.0689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。